GlassScriptPhysician profile
Marles J Geist
NPI 1073759486
$1,558.70
in general payments reported to CMS, 2019-2025
19 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $638 · 2023: $135 · 2024: $43.59 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.63 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $357.98 | 2021-2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $325.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $179.18 | 2021-2025 | Calquence |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Genzyme Corporation | $98.62 | 2021-2025 | |
| Abbvie INC. | $89.39 | 2023-2025 | |
| Eisai INC. | $63.81 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $58.16 | 2021-2023 | Imbruvica |
| Celgene Corporation | $54.04 | 2022 | |
| Lilly USA, LLC | $45.47 | 2023-2025 | Jaypirca, Verzenio |
| Astellas Pharma US INC | $29.32 | 2021-2023 | Xtandi |
| Seagen INC. | $27.88 | 2023 | Tukysa |
| Cti Biopharma Corp. | $25.08 | 2022 | |
| Daiichi Sankyo INC. | $24.67 | 2021 | |
| Genentech USA, INC. | $22.62 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $18.43 | 2021 | |
| Blueprint Medicines Corporation | $14.08 | 2021 | |
| Rigel Pharmaceuticals, INC. | $12.50 | 2023 | Rezlidhia, Tavalisse |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marles Geist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.